The management of patients with localized and advanced breast cancer continues to evolve. Chemotherapy, endocrine therapy, and trastuzumab are effective therapies but leave considerable room for improvement. As the cellular aberrations inherent to cancer cells in general and breast cancer cells specifically are better understood, therapies to target specific cellular pathways continue to be developed with the goal of expanding available effective therapy through better patient selection.
Methods:
We conducted a computerized search of the medical literature as well as a manual search of selected meeting abstracts.
Results:
Several targeted therapies are in phase III clinical trials testing their promise in the treatment of breast cancer. Many other agents are completing phase I and II testing. An overview of the most promising agents in clinical development is discussed herein.
Conclusions:
Targeted therapy for breast cancer is a reality at this time, and several new agents hold promise for expanding and refining the pool of patients likely to further benefit from this approach in the near future.
References
1.
JemalA., MurrayT., WardE.. Cancer statistics, 2005.CA Cancer J Clin.2005; 55: 10–30.
2.
BuzdarA.U.. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.Oncologist.2003; 8: 335–341.
3.
SlamonD.J., Leyland-JonesB., ShakS.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med.2001; 344: 783–792.
4.
ExtraJ.M., CognettiF., ChanS.. First-line trastuzumab (Herceptin) plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): results from a randomised phase II trial (M77001).Breast Cancer Res Treat.2003; 82(Suppl 1): S47. Abstract 217.
5.
Early Breast Cancer Trialists’ Colaborative Group.Tamoxifen for early breast cancer: an overview of the randomised trials.Lancet.1998; 351: 1451–1467.
6.
IngleJ.N., TwitoD.I., SchaidD.J.. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.J Clin Oncol.1988; 6: 825–831.
7.
BonneterreJ., BuzdarA., NabholtzJ.M.. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis.Cancer.2001; 92: 2247–2258.
8.
EllisM.J., CoopA., SinghB.. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.J Clin Oncol.2001; 19: 3808–3816.
9.
SmithI., DowsettM., on behalf of the IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial.Breast Can Res Treat.2003; 82: S6. Abstract 1.
10.
BaumM., BudzarA.U., CuzikJ.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.Lancet.2002; 359: 2131–2139. Erratum in: Lancet. 2002;360: 1520.
11.
DowsettM., on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (arimedex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status.Breast Can Res Treat.2003; 82: S7. Abstract 4.
12.
AtalayG., CardosoF., AwadaA.. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.Ann Oncol.2003; 14: 1346–1363.
13.
LinN.U., WinerE.P.. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors.Breast Cancer Res.2004; 6: 204–210.
14.
EmensL.A., DavidsonN.E.. Trastuzumab in breast cancer.Oncology (Huntingt).2004; 18: 1117–1128.
15.
VogelC.L., CobleighM.A., TripathyD.. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J Clin Oncol.2002; 20: 719–726.
16.
CobleighM.A., VogelC.L., TripathyD.. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol.1999; 17: 2639–2648.
17.
PegramM.D., KonecnyG.E., O'CallaghanC.. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.J Natl Cancer Inst.2004; 96: 739–749.
18.
BaselgaJ., CarbonellX., Castaneda-SotoN.J.. Updated efficacy and safety analyses of 3-weekly Herceptin® monotherapy in women with HER2-positive metastatic breast cancer: results from twelve months of follow-up to a phase II study.Breast Can Res Treat.2004; 88(Suppl 1): S126. Abstract 3042.
19.
AlbainK., ElledgeR., GradisharW.J.. Open-label, phase II, multicenter trial of ZD1839 (“Iressa”) in patients with advanced breast cancer.Breast Can Res Treat.2002; 76: S33. Abstract 20.
20.
RobertsonJ.F.R., GutteridgeE., CheungK.L.. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM) resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study.Proc Annu Meet Am Soc Clin Oncol.2003; 22: 7. Abstract 23.
21.
BaselgaJ., AlbanellJ., RuizA.. Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer.Proc Annu Meet Am Soc Clin Oncol.2003; 22: 7. Abstract 24.
22.
WinerE., CobleighM., DicklerM.. Phase II multicenter study to evaluate the efficacy and safety of Tarceva™ (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer.Breast Can Res Treat.2002; 76: S115. Abstract 445.
23.
CunninghamD., HumbletY., SienaS.. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med.2004; 351: 337–345.
24.
MendelsohnJ., BaselgaJ.. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.J Clin Oncol.2003; 21: 2787–2799.
25.
RusnakD.W., LackeyK., AffleckK.. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.Mol Cancer Ther.2001; 1: 85–94.
26.
XiaW., MullinR.J., KeithB.R.. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.Oncogene.2002; 21: 6255–6263.
27.
BurrisH., HurwitzH., DeesC.. EGF10004: a randomized, multicenter, phase Ib study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor GW572016.Breast Can Res Treat.2003; 82. Abstract 39.
28.
MaungK.. Inhibition of ErbB1 and ErbB2 by lapatinib ditosylate, a dual kinase inhibitor: promising activity in pretreated advanced breast cancer.Clin Breast Cancer.2004; 4: 398–400.
29.
BlackwellK.L., KaplanE.H., FrancoS.X.. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.Proc Annu Meet Am Soc Clin Oncol.2004; 22 (14S): 3006. Abstract.
30.
PriceN., ReddyG.K., TyagiP.. Highlights from Third Annual Future of Breast Cancer: An International Congress.Clin Breast Cancer.2004; 5: 172–176.
31.
AgusD.B., GordonM., TaylorC.. Clinical activity in a phase I trial of HER-2-targeted rhuMAb2C4 (pertuzumab) in patients with advanced solid malignancies (AST).Proc Annu Meet Am Soc Clin Oncol.2003; 22: 192. Abstract 771.
32.
AllenL.F., EisemanI.A., FryD.W.. CI-1033, an Irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.Semin Oncol.2003; 30 (5 suppl 16): 65–78.
33.
ArteagaC.L., O'NeilA., MoulderS.L.. ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib (“Iressa”) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca).Breast Can Res Treat.2004; 88: S15. Abstract 25.
34.
BurrisH.A.IIIStornioloA.M., OvermoyerE.A.. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab.Breast Can Res Treat.2004; 88: S126. Abstract 3043.
35.
ArpinoG., WeissH., WakelingA.E.. Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition.Breast Can Res Treat.2004; 88: S15. Abstract 23.
36.
WeidnerN., FolkmanJ., PozzaF.. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.J Natl Cancer Inst.1992; 84: 1875–1887.
37.
SyedS., RowinskyE.. The new generation of targeted therapies for breast cancer.Oncology (Huntingt).2003; 17: 1339–1356.
38.
HurwitzH., FehrenbacherL., NovotnyW.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med.2004; 350: 2335–2342.
39.
CobleighM.A., LangmuirV.K., SledgeG.W.. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.Semin Oncol.2003; 30: 117–124.
40.
MillerK.D., ChapL.I., HolmesF.A.. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.J Clin Oncol.2005; 23: 792–799.
41.
de BonoJ.S., TolcherA.W., RowinskyE.K.. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.Semin Oncol.2003; 30 (5 suppl 16): 79–92.
42.
GibbsJ.B., OliffA., KohlN.E.. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.Cell.1994; 77: 175–178.
43.
JohnstonS.R., HickishT., EllisP.. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.J Clin Oncol.2003; 21: 2492–2499.
44.
LoRussoP.M., AdjeiA.A., MeyerM.B.. A phase 1 clinical and pharmacologic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer.Proc Annu Meet Am Soc Clin Oncol.2002; 21: 81a. Abstract 321.
45.
RinehartJ., AdjeiA.A., LorussoP.M.. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.J Clin Oncol.2004; 22: 4456–4462.
46.
CarrawayH., HidalgoM.. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.Breast Cancer Res.2004; 6: 219–224.
47.
CampbellI.G., RussellS.E., ChoongD.Y.H.. Mutation of the PIK3CA gene in ovarian and breast cancer.Cancer Res.2004; 64: 7678–7681.
48.
ChanS., ScheulenM.E., JohnstonS.. Final results of a phase 2 study of single-agent CCI-779 in locally advanced or metastatic breast cancer failing prior anthracycline and/or taxane regimens.Breast Can Res Treat.2003; 82: S82. Abstract 346.
49.
BaselgaJ., FumoleauP., GilM.. Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results.Proc Annu Meet Am Soc Clin Oncol.2004; 22 (14S): 544. Abstract.
50.
AdamsJ.. Proteasome inhibitors as new anticancer drugs.Curr Opin Oncol.2002; 14: 628–634.
51.
BrownJ., Von RoennJ., O'ReganR.. A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC).J Clin Oncol.2004; 22 (14S): 546. Abstract.
